Kiora Pharmaceuticals Inc
KPRX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001372514
No open-market purchases or sales by Kiora Pharmaceuticals Inc insiders were filed in the last 90 days; 22 institutions reported holding it in 13F filings for Q2 2026, worth $2.91M in total; no superinvestor holds it.
Other share classesKPHMW
Q2 2022 vs. Q1 2022
How the institutions holding Kiora Pharmaceuticals Inc changed between Q1 2022 and Q2 2022.
All holders in Q2 2022All holders in Q1 2022
| Measure | Q1 2022 | Q2 2022 | Change |
|---|---|---|---|
| Holders | 16 | 14 | −2 |
| Shares | 831.4K | 836.2K | +4.72K (+0.6%) |
| Value | $517.0K | $391.0K | −$126.0K (−24.4%) |
New holders (2)
Institutions that held Kiora Pharmaceuticals Inc at the end of Q2 2022 but not at the end of Q1 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Citadel Advisors LLC | 46,440 | $22.0K | 0.00% |
| Captrust Financial Advisors | 15,000 | $7.00K | 0.00% |
Sold out (4)
Institutions that held Kiora Pharmaceuticals Inc at the end of Q1 2022 and filed for Q2 2022 without it.
| Institution | Shares, Q1 2022 | Value, Q1 2022 |
|---|---|---|
| Ergoteles LLC | 17,800 | $11.0K |
| Goldman Sachs Group Inc | 13,275 | $8.00K |
| Susquehanna International Group, LLP | 11,330 | $7.00K |
| Citigroup Inc | 1,000 | $1.00K |